Ms. O’Farrell also serves as a member of the board of directors of LENSAR, Inc., a global medical technology company, since February 2021, and Genmab A/S, a global oncology company, since March 2022. She served as a member of the board of directors of Inhibikase Therapeutics, a pharmaceutical company focused on treatments of neurological infections and neurodegenerative diseases, from March 2019 to September 2022. Ms. O’Farrell also served as a board member of the YMCA of Greater Indianapolis from 2006 until 2017, including as its chairperson from 2014 to 2016. In December 2017, Ms. O’Farrell retired from a 24-year career with Eli Lilly and Company, a global pharmaceutical company, where she held several senior management positions in finance and corporate governance, most recently serving as Chief Procurement Officer and Head of Global Shared Services from January 2012 to December 2017.
Prior to that position, she also served as Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company, a professional accountancy firm, and Price Waterhouse, an international public accounting firm. Ms. O’Farrell holds a B.S. in accounting with honors and an M.B.A. in management information systems, both from Indiana University.
What is Elizabeth G. O'Farrell's net worth?
The estimated net worth of Elizabeth G. O'Farrell is at least $9,888.35 as of August 24th, 2023. Ms. O'Farrell owns 7,407 shares of Geron stock worth more than $9,888 as of April 22nd. This net worth estimate does not reflect any other assets that Ms. O'Farrell may own. Learn More about Elizabeth G. O'Farrell's net worth.
How do I contact Elizabeth G. O'Farrell?
Has Elizabeth G. O'Farrell been buying or selling shares of Geron?
Elizabeth G. O'Farrell has not been actively trading shares of Geron within the last three months. Most recently, on Thursday, August 24th, Elizabeth G. O'farrell bought 6,607 shares of Geron stock. The stock was acquired at an average cost of $2.28 per share, with a total value of $15,063.96. Following the completion of the transaction, the director now directly owns 7,407 shares of the company's stock, valued at $16,887.96. Learn More on Elizabeth G. O'Farrell's trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
